{
    "id": 19487,
    "cites": 53,
    "cited_by": 3,
    "reference": [
        "Aitken, Murray L. and Ernst R. Berndt [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicare Part D at Age Five: What Has Happened to Seniors\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Prescription Drug Prices?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Report by the IMS Institute for Healthcare Bioinformatics, July.",
        "Aitken, Murray L., Ernst R. Berndt and David M. Cutler [2008], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Prescription Drug Spending Trends in the United States: Looking Beyond The Turning Point\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Health Affairs Web Exclusive 28(1):W151-60, 2009. Published online 16 December 2008, 10.1377/hlthaff.28.1.w151.",
        "Alpert, Abby, Mark Duggan and Judith K. Hellerstein [2013], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Perverse Reverse Price Competition: Average Wholesale Prices and Medicaid Pharmaceutical Spending\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, August. Available from lead author at aealpert@uci.edu. Cambridge, MA: National Bureau of Economic Research, Working Paper, forthcoming September. Forthcoming, Journal of Public Economics.",
        "Appelt, Silvia [2013], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Authorized Generic Entry Prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Working Paper, University of Munich, May. Available from the author at silvia.appelt@lrz.uni-muenchen.de.",
        "Avalere Health LLC [2010], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093State Policies Regarding Generic Substitution, 2010\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d. Powerpoint presentation. Available online at www.avalerehealth.net/research/docs/Generic_Substitution.pdf.",
        "Berndt, Ernst R. and Murray L. Aitken [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, International Journal of the Economics of Business 18(2):177-201, July 2011.",
        "Berndt, Ernst R., Iain M. Cockburn and Zvi Griliches [1996], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmaceutical Innovation and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Brookings Papers on Economic Activity: Microeconomics 1996(2):1133-88.",
        "Berndt, Ernst R., David M. Cutler, Richard G. Frank, Zvi Griliches, Joseph P. Newhouse and Jack E. Triplett [2000], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medical Care Prices and Output\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, ch. 3 in Anthony Culyer and Joseph P. Newhouse, eds., Handbook of Health Economics, Amsterdam and New York: Elsevier Sciences B.V., Vol. 1A:11780.",
        "Berndt, Ernst R., Richard Mortimer, Ashoke M. Bhattacharjya, Andrew Parece and Edward Tuttle [2007], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Authorized Generic Drugs, Price Competition, and Consumers\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Welfare\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Health Affairs 26(3):790-799, May/June.",
        "Berndt, Ernst R. and Joseph P. Newhouse [2012], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pricing and Reimbursement in US Pharmaceutical Markets\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, ch. 8 in Patricia M. Danzon and Sean Nicholson, eds., The Oxford Handbook of the Economics of the Biopharmaceutical Industry, New York: Oxford University Press, 201-265.",
        "Branstetter, Lee G., Chirantan Chatterjee and Matthew J. Higgins [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Cambridge, MA: National Bureau of Economic Research, Working Paper 17188, June.",
        "Generics and Loss of Exclusivity 2013 23 Brill, Alex [2010], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Overspending on Multi-Source Drugs in Medicaid\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Washington DC: American Enterprise Institute, AEI Health Policy Studies Working Paper @2010-01, July 21. Available online at http://www.aei.org/paper/100127.",
        "Caves, Richard E., Michael D. Whinston and Mark A. Hurwitz [1991], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Brookings Papers on Economic Activity: Microeconomics, 1991, 1-66.",
        "Centers for Medicare & Medicaid Services [2012]. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Survey of Retail Prices\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, May 31. Available online at http://medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/PrescriptionDrugs /Survey-of-Retail-Prices.html.",
        "Cook, Anna [1998], How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry, Washington DC: The Congress of the United States, Congressional Budget Office. Available online at http://www.cbo.gov/.",
        "Drug Channels [2012], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pfizer\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Lipitor Strategy and the 2012 Generic Monster\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, March 15. Available online at http://www.drugchannels.net/2012/03/pfizers-lipitor-strategy-and-2012.html.",
        "Drug Channels [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Ranbaxy Makes Three: The Battle for Generic Lipitor Profits\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, December 1.",
        "Drug Facts and Comparisons 2011 Edition [2011], St. Louis, MO: Wolters Kluwer Health, Inc.",
        "Ellison, Glenn and Sara Fisher Ellison [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, American Economic Journal: Microeconomics 3(1):1-36.",
        "Ellison, Sara Fisher, Iain M. Cockburn, Zvi Griliches and Jerry A. Hausman [1997], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, RAND Journal of Economics 28(3):426-46.",
        "Federal Trade Commission [2011], Authorized Generic Drugs: Short-Term Effects and Long-Term Impact, August. Available online at http://www.ftc.gov/opa/2011/08/genericdrugs.shtm.",
        "Federal Trade Commission [2009], Authorized Generics: An Interim Report of the Federal Trade Commission, June 24. Available online at http://www.ftc.gov/os/2009/06/P062105authorizedgenericsreport.pdf.",
        "Federal Trade Commission [2002], Generic Drug Entry Prior to Patent Expiration: An FTC Study, July.",
        "FiercePharma [2012], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Top 15 drug patent losses for 2013\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, November 1. Available online at http://www.fiercepharma.com/special-reports/top-15-patent-expirations-2013.",
        "Frank, Richard G. and David S. Salkever [1997], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Entry and the Pricing of Pharmaceuticals\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Economics and Management Strategy 6(1):75-90.",
        "Generics and Loss of Exclusivity 2013 24 Frank, Richard G. and David S. Salkever [1992], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pricing, Patent Loss and the Market for Pharmaceuticals\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Southern Economic Journal 59:165-79.",
        "Generic Pharmaceutical Association [2013], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Industry by the Numbers\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Generic Pharmaceutical Association 2012 Annual Report. Available online at www.gphaonline.org.",
        "Generic Pharmaceutical Association [2012], Generic Drug Savings in the U.S.: Savings $1 Trillion Over 10 Years, Fourth Annual Edition, August 2. Available online at www.gphaonline.org.",
        "Grabowski, Henry G., Margaret K. Kyle, Richard Mortimer, Genia Long and Noam Kirson [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Health Affairs 30(11):2157-66, November.",
        "Grabowski, Henry G. and Margaret K. Kyle [2007], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Competition and Market Exclusivity Periods in Pharmaceuticals\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Managerial Decision and Economics 28:491-502.",
        "Grabowski, Henry G., Genia Long and Richard Mortimer [2013], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Biosimilars\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, unpublished manuscript, Duke University, August. Forthcoming as ch. 12.8 in Patricia Danzon, ed., Encyclopedia of Health Economics, New York: Elsevier.",
        "Grabowski, Henry G., Genia Long and Richard Mortimer [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Implementation of the Biosimilar Pathway: Economic and Policy Issues\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Seton Hall Law Review 41(2):511-557 Grabowski, Henry G. and John M. Vernon [1996], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Longer Patents for Increased Generic Competition in the US: The Waxman-Hatch Act After One Decade\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, PharmacoEconomics 10 Suppl2:110-123.",
        "Grabowski, Henry G. and John M. Vernon [1992], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Brand Loyalty, Entry, and Price Competition in Pharmaceuticals After the 1984 Drug Act\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Law and Economics 35:331-350, October.",
        "Hemphill, C. Scott and Bhaven N. Sampat [2012], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Health Economics 31(2):327-39, March.",
        "Hurwitz, Mark A. and Richard E. Caves [1988], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Law and Economics 31:299-320, October.",
        "Huskamp, Haiden A., Julie M. Donohue, Catherine Koss, Ernst R. Berndt and Richard G. Frank [2008], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Entry, Reformulations, and Promotion of SSRIs\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, PharmacoEconomics 26(7):603-16.",
        "IMS Institute for Healthcare Informatics [2013], Declining Medicine Use and Costs: For Better or Worse?, May. Available online at www.theimsinstitute.org.",
        "Kelton, Christina M. L, Lenisa V. Chang and David H. Kreling [2013], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093State Medicaid Programs Missed $220 Million in Uncaptured Savings As Generic Fluoxetine Came to Market, 2001-05\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Health Affairs 32(7):1204-11, July.",
        "Generics and Loss of Exclusivity 2013 25 Medicaid Drug Rebate Program [2013], last updated August 15, 2013. Available online at http://www.medicaid.gov.",
        "Olson, Luke M. and Brett W. Wendling [2013], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of Generic Drug Competition on Generic Drug Prices During the Hatch-Waxman 180-Day Exclusivity Period\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Washington DC: Federal Trade Commission, Bureau of Economics, Working Paper No. 317, April. Available online at bwendling@ftc.gov.",
        "Panattoni, Laura E. [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of Paragraph IV Decisions and Generic Entry Before Patent Expiration on Brand Pharmaceutical Firms\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Health Economics 30(1):126-45.",
        "Regan, Tracy L. [2008], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Entry, Price Competition, and Market Segmentation in the Prescription Drug Market\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, International Journal of Industrial Organization 26(4):930-48.",
        "Reiffen, David E. and Michael E. Ward [2007], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2Branded Generics\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 as a Strategy to Limit Cannibalization of Pharmaceutical Markets\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Managerial and Decision Economics 28:251.267.",
        "Reiffen, David E. and Michael E. Ward [2005], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Drug Industry Dynamics\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Review of Economics and Statistics 87(1):37-49.",
        "Saha, Atanu, Henry G. Grabowski, Howard M. Birnbaum, Paul E. Greenberg and Oded Bizan [2006], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Competition in the U.S. Pharmaceutical Industry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, International Journal of the Economics of Business 13(1):15-38, February.",
        "Scott Morton, Fiona M. [2000], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Barriers to Entry, Brand Advertising and Generic Entry in the U.S. Pharmaceutical Industry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, International Journal of Industrial Organization 18:1085-104.",
        "Scott Morton, Fiona M. [1999], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Entry Decisions in the Generic Pharmaceutical Industry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, The RAND Journal of Economics 30:421-440.",
        "Smith, Aaron [2007], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Federal judge whacks generic Plavix\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, CNN Money.com, June 10, 2007.",
        "Somers, Julie [2010], Effects of Using Generic Drugs on Medicare\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Prescription Drug Spending, Washington DC: The Congress of the United States, Congressional Budget Office, September. Available online at http://www.cbo.gov/.",
        "U.S. Department of Labor, Bureau of Labor Statistics [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Pharmaceutical Industry: An Overview of CPI, PPI, and IPP Methodology\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Office of Prices & Living Conditions, October. Available online at http://www.bls.gov/ppi/pharmpricescomparison.pdf.",
        "Wang, Xiangnong [2012], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Understanding Current Trends and Outcomes in Generic Drug Patent Litigation: An Empirical Investigation\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, unpublished Masters\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 honors thesis, Stanford University: Public Policy Program, May.",
        "Wiggins, Steven N. and Robert Maness [2004], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Price Competition in Pharmaceuticals: The Case of AntiInfectives \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Economic Inquiry 42(2):247-63.",
        "Generics and Loss of Exclusivity 2013 26 Wosinska, Marta and Robert S. Huckman [2004], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Dispensing and Substitution in Mail and Retail Pharmacies\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Health Affairs \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c Web Exclusive, W4-409 to W4-416, posted 28 July 2004. Available online at www.healthaffairs.org. An abstract of the article was published in the hardcopy edition of Health Affairs 23(5):284, September/October 2004."
    ]
}